Troriluzole Fails to Ease Cognitive Impairments in Phase 2/3 Trial

Troriluzole Fails to Ease Cognitive Impairments in Phase 2/3 Trial

285069

Troriluzole Fails to Ease Cognitive Impairments in Phase 2/3 Trial

Troriluzole, an investigational oral symptomatic treatment developed by Biohaven for Alzheimer’s disease, did not work better than a placebo in alleviating cognitive impairments and reducing brain volume loss in patients with mild-to-moderate disease, according to top-line data from a Phase 2/3 trial. However, a subgroup analysis — performed in the subset of study patients with milder forms of Alzheimer’s — suggested troriluzole might help preserve cognitive abilities and brain volume in people at the earlier…

You must be logged in to read/download the full post.